Atlas Trials

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Clinical trial NCT05308654 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05308654
Sponsor
AbbVie
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory Multiple Myeloma
Start date
2022-05-17
Primary completion
2024-02-07
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.